Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Beginning Cash Balance (2017 - 2022)

China Pharma Holdings' Beginning Cash Balance history spans 9 years, with the latest figure at -$4026.0 for Q4 2022.

  • For Q4 2022, Beginning Cash Balance fell 101.3% year-over-year to -$4026.0; the TTM value through Dec 2022 reached $223013.0, down 60.36%, while the annual FY2022 figure was $223013.0, 60.36% down from the prior year.
  • Beginning Cash Balance reached -$4026.0 in Q4 2022 per CPHI's latest filing, up from -$4317.0 in the prior quarter.
  • In the past five years, Beginning Cash Balance ranged from a high of $310783.0 in Q4 2021 to a low of -$4850.0 in Q2 2022.
  • Average Beginning Cash Balance over 4 years is $102821.2, with a median of $111691.0 recorded in 2019.
  • Peak YoY movement for Beginning Cash Balance: skyrocketed 172.36% in 2021, then tumbled 28880.0% in 2022.
  • A 4-year view of Beginning Cash Balance shows it stood at $111691.0 in 2019, then grew by 2.16% to $114109.0 in 2020, then skyrocketed by 172.36% to $310783.0 in 2021, then plummeted by 101.3% to -$4026.0 in 2022.
  • Per Business Quant, the three most recent readings for CPHI's Beginning Cash Balance are -$4026.0 (Q4 2022), -$4317.0 (Q3 2022), and -$4850.0 (Q2 2022).